Amgen (AMGN): FY25 Q3 earnings call, Nov 4, 2025
No Kalshi or Polymarket word markets were listed for Amgen’s Nov 4, 2025 earnings call (FY25 Q3). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
2 matches for “Oral”; 2 quoted, at least 25 words apart.
…of rising preclinical candidates for both incretin and non-incretin targets, featuring both oral and injectable routes of administration. Beyond obesity, in general medicine, as Murdo…
…for novel targets within the incretin and non-incretin pathways. Some will be oral, some will be injectable. And so we're really in it to have…
Agents: this page as TSV at /api/v1/appearances/amgen:2025-11-04:earnings_call · words: /api/v1/brief?appearance=amgen:2025-11-04:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP